The next few weeks will put Bristol-Myers Squibb's narrowed drug making strategy to a test. Just after Labor Day, FDA advisory councils will take up the marketing applications for the rheumatoid arthritis drug Orencia and Pargluva for diabetes. The potential blockbusters are considered critical for the future success of the company, according to The New York Times, and the safety questions that linger around Pargluva may make it hard to gain approval from a more skeptical FDA.
- read this article in The New York Times for more